相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study
Fabian Trillsch et al.
GYNECOLOGIC ONCOLOGY (2022)
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Philipp Harter et al.
GYNECOLOGIC ONCOLOGY (2022)
Older adult participation in cancer clinical trials: A systematic review of barriers and interventions
Mina S. Sedrak et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women
Olga T. Filippova et al.
GYNECOLOGIC ONCOLOGY (2021)
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer A Randomized Clinical Trial
Claire Falandry et al.
JAMA ONCOLOGY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
Anna Fagotti et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
The PARP Inhibitor Olaparib Modulates the Transcriptional Regulatory Networks of Long Non-Coding RNAs during Vasculogenic Mimicry
Monica Fernandez-Cortes et al.
CELLS (2020)
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
Roshni D. Kalachand et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Olaparib treatment in older patients with ovarian cancer: need for 'real-world' data beyond clinical trials
Gabor Liposits et al.
ECANCERMEDICALSCIENCE (2020)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N. Colombo et al.
ANNALS OF ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain)
Ainara Ruiz de Sabando et al.
BMC CANCER (2019)
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Michel Fabbro et al.
GYNECOLOGIC ONCOLOGY (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper
Gabor Liposits et al.
JOURNAL OF GERIATRIC ONCOLOGY (2019)
Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study
Frederic Selle et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2018)
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
Ignace Vergote et al.
LANCET ONCOLOGY (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer
Lauren E. Dockery et al.
GYNECOLOGIC ONCOLOGY (2017)
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Roberto Sorio et al.
GYNECOLOGIC ONCOLOGY (2017)
Contribution of age to clinical trial enrollment and tolerance with ovarian cancer
Jessica Gillen et al.
GYNECOLOGIC ONCOLOGY (2017)
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study
Vivian E. von Gruenigen et al.
GYNECOLOGIC ONCOLOGY (2017)
Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival
Ahmedin Jemal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival
Ahmedin Jemal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Application and Outcome of Standard of Care Treatment in elderly women with Ovarian Cancer: A Literature Review over the Last 10 Years
Steven J. Gibson et al.
FRONTIERS IN ONCOLOGY (2016)
Prognostic Factors for Ovarian Epithelial Cancer in the Elderly A Case-Control Study
Renaud Sabatier et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2015)
Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement
Arti Hurria et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer
Jason D. Wright et al.
CANCER (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial
C. Falandry et al.
ANNALS OF ONCOLOGY (2013)
Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress
Kevin S. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer?: Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
O. Tredan et al.
ANNALS OF ONCOLOGY (2007)
分享论文
